Opthea Limited
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Optheaâs Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone
+6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV â a subtype of AMD, prevalent among Asian populations with high unmet medical need
MELBOURNE, Australia, Feb. 14, 20...
>>> Read more: Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Optheaâs Phase 2b clinical trial of OPT-302 in combination with ranibizumab (Lucentis®), compared to ranibizumab alone
+6.7 letters comparative superiority of 2 mg OPT-302 combination therapy (p = 0.0253) in patients with PCV â a subtype of AMD, prevalent among Asian populations with high unmet medical need
MELBOURNE, Australia, Feb. 14, 20...
>>> Read more: Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022
